ClinicalTrials.gov Search Results 01/10/2019

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
1	NCT01624480	Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Armodafinil in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy Study Documents:	Title Acronym: Other Ids: •C10953/1100 •2012-005510-20	Completed	•Narcolepsy	•Drug: Armodafinil	Study Type: Interventional Phase: Phase 1 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Maximum observed plasma drug concentration (Cmax) by inspection •Time to maximum observed plasma drug concentration (tmax) by inspection •Area under the plasma drug concentration by time curve from time 0 to infinity •Area under the plasma drug concentration by time curve from time 0 to the time of the last measurable drug concentration •Terminal half-life •Terminal elimination rate constant •Apparent total plasma clearance •Apparent volume of distribution •Predicted accumulation ratio •Maximum observed plasma drug concentration (Cmax) •and 7 more	Enrollment: 40 Age: 6 Years to 17 Years (Child) Sex: All	•Teva Pharmaceutical Industries	•Industry	Study Start: July 2012 Primary Completion: September 2015 Study Completion: December 2015 First Posted: June 20, 2012 Results First Posted: No Results Posted Last Update Posted: December 9, 2015	•Teva Investigational Site 12, Birmingham, Alabama, United States •Teva Investigational Site 17, Birmingham, Alabama, United States •Teva Investigational Site 7, Little Rock, Arkansas, United States •Teva Investigational Site 18, Orange, California, United States •Teva Investigational Site 16, San Diego, California, United States •Teva Investigational Site 4, Stanford, California, United States •Teva Investigational Site 9, Clearwater, Florida, United States •Teva Investigational Site 26, Miami Lakes, Florida, United States •Teva Investigational Site 5, Spring Hill, Florida, United States •Teva Investigational Site 25, Winter Park, Florida, United States •and 14 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
2	NCT00107796	Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy Study Documents:	Title Acronym: Other Ids: C1538/3027/NA/ MN-Narcolepsy	Completed	•Narcolepsy	•Drug: Modafinil	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Double •Primary Purpose: Treatment Outcome Measures: •Mean sleep latency from the Multiple Sleep Latency Test (MSLT) (average of 4 naps performed at 0900, 1100, 1300, and 1500) at the last post baseline observation (week 6 or early termination) •The Clinical Global Impression of Change (CGI-C) ratings for ES, at the last post baseline observation (week 6 or early termination) •Clinical Global Impression of Change (CGI-C) ratings for ES at weeks 3 and 6 •Total score from the Pediatric Daytime Sleepiness Scale (PDSS) at weeks 3 and 6, and last postbaseline observation •Mean sleep latency from the MSLT (average of 4 naps performed at 0900, 1100, 1300, and 1500) at week 6	Enrollment: 140 Age: 6 Years to 16 Years (Child) Sex: All	•Cephalon •Teva Pharmaceutical Industries	•Industry	Study Start: October 2004 Primary Completion: Study Completion: September 2005 First Posted: April 11, 2005 Results First Posted: No Results Posted Last Update Posted: August 24, 2012	•Robert Doekel, Jr., M.D., Birmingham, Alabama, United States •Chris M. Makris, M.D., Birmingham, Alabama, United States •Barbara Harris, Ph.D., Phoenix, Arizona, United States •Derek Loewy, Ph.D., Tucson, Arizona, United States •Stuart Quan, M.D., Tucson, Arizona, United States •Joseph McCarty, M.D., Fort Smith, Arkansas, United States •John L. Carroll, M.D., Little Rock, Arkansas, United States •Samuel Boellner, M.D., Little Rock, Arkansas, United States •Julie Thompson-Dobkin, D.O., Huntington Beach, California, United States •Mark Buchfuhrer, M.D., Long Beach, California, United States •and 63 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
3	NCT00107848	PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome Study Documents:	Title Acronym: Other Ids: C1538/3029/ES/ MN-Open label	Completed	•Narcolepsy •Sleep Apnea, Obstructive	•Drug: Modafinil	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Non-Randomized •Intervention Model: Single Group Assignment •Primary Purpose: Treatment Outcome Measures: •The primary objective of the study is to evaluate the safety and tolerability of treatment with PROVIGIL in children and adolescents with excessive sleepiness (ES) associated with narcolepsy or OSAHS, when administered for up to 12 months. •The secondary objective of the study is to evaluate long-term effectiveness by using: the Clinical Global Impression of Change (CGI C) ratings for severity of ES and the total score from the Pediatric Daytime Sleepiness Scale (PDSS)	Enrollment: 280 Age: 6 Years to 16 Years (Child) Sex: All	•Cephalon •Teva Pharmaceutical Industries	•Industry	Study Start: October 2004 Primary Completion: Study Completion: September 2005 First Posted: April 11, 2005 Results First Posted: No Results Posted Last Update Posted: May 9, 2014	•Robert Doekel, Jr., M.D., Birmingham, Alabama, United States •Chris M. Makris, M.D., Birmingham, Alabama, United States •Barbara Harris, Ph.D., Phoenix, Arizona, United States •Derek Loewy, Ph.D., Tucson, Arizona, United States •Joseph McCarty, M.D., Fort Smith, Arkansas, United States •Samuel Boellner, M.D., Little Rock, Arkansas, United States •Julie Thompson-Dobkin, D.O., Huntington Beach, California, United States •Mark Buchfuhrer, M.D., Long Beach, California, United States •Yury Furman, M.D., Los Angeles, California, United States •Stuart Menn, M.D., Palm Springs, California, United States •and 51 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
4	NCT03772314	Modafinil Versus Amphetamines for the Treatment of Narcolepsy Type 2 and Idiopathic Hypersomnia Study Documents:	Title Acronym: Other Ids: IRB00108167	Not yet recruiting	•Idiopathic Hypersomnia •Narcolepsy Without Cataplexy	•Drug: Modafinil •Drug: Amphetamine-Dextroamphetamine	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: •Change in Epworth Sleepiness Scale (ESS) Score •Change in Patient Global Impression of Change (PGIc) for Sleepiness Score •Change in Patient Global Impression of Change (PGIc) for Sleep Inertia Score •Change in Patient Global Impression of Change (PGIc) for Cognitive Dysfunction Score	Enrollment: 44 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Emory University •American Academy of Sleep Medicine	•Other	Study Start: March 2019 Primary Completion: February 2022 Study Completion: February 2022 First Posted: December 11, 2018 Results First Posted: No Results Posted Last Update Posted: December 11, 2018	•Emory Sleep Center, Atlanta, Georgia, United States
5	NCT00214968	Assess the Safety and Effectiveness of PROVIGIL Treatment in Children and Adolescents With Excessive Sleepiness Study Documents:	Title Acronym: Other Ids: C1538/3034/ES/MN	Completed	•Narcolepsy	•Drug: Modafinil	Study Type: Interventional Phase: Phase 3 Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Adverse event evaluations •Composite Ratings of severity of illness •Total score from the Pediatric Daytime Sleepiness Scale (PDSS)	Enrollment: 92 Age: 6 Years to 16 Years (Child) Sex: All	•Cephalon •Teva Pharmaceutical Industries	•Industry	Study Start: January 2005 Primary Completion: October 2005 Study Completion: October 2005 First Posted: September 22, 2005 Results First Posted: No Results Posted Last Update Posted: May 31, 2012	

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
6	NCT00228553	Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness Study Documents:	Title Acronym: Other Ids: C10953/3024/ES/MN	Completed	•Excessive Daytime Sleepiness •Narcolepsy •Obstructive Sleep Apnea/Hypopnea Syndrome •Chronic Shift Work Sleep Disorder	•Drug: Armodafinil 100 to 250 mg/day	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Non-Randomized •Intervention Model: Factorial Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: Safety and Tolerability in This Patient Population (Narcolepsy, OSAHS, SWSD) Over Time (up to 2 Years)	Enrollment: 743 Age: 18 Years to 65 Years (Adult, Older Adult) Sex: All	•Cephalon •Teva Pharmaceutical Industries	•Industry	Study Start: May 2004 Primary Completion: Study Completion: July 2006 First Posted: September 29, 2005 Results First Posted: March 31, 2010 Last Update Posted: July 19, 2013	•Sleep Disorders Ctr of Alabama, Birmingham, Alabama, United States •Pulmonary Associates, PA, Phoenix, Arizona, United States •Psypharma Clinical Research, Phoenix, Arizona, United States •Central Arkansas Research, Hot Springs, Arkansas, United States •Advanced Clinical Research Ins, Anaheim, California, United States •Southwestern Research, Beverly Hills, California, United States •Pacific Sleep Medicine Service, Los Angeles, California, United States •Pacific Sleep Medicine Service, Palm Springs, California, United States •Radiant Research San Diego, San Diego, California, United States •Pacific Sleep Medicine Service, San Diego, California, United States •and 90 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
7	NCT00228566	Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome Study Documents:	Title Acronym: Other Ids: C10953/3046/ES/US	Completed	• Excessive Daytime Sleepiness • Narcolepsy • Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS)	• Drug: Armodafinil	Study Type: Interventional Phase: Phase 3 Study Design: • Allocation: Non-Randomized • Intervention Model: Single Group Assignment • Masking: None (Open Label) • Primary Purpose: Treatment Outcome Measures: Number of Responders to the Patient Global Impression of Change (PGI-C) Ratings	Enrollment: 247 Age: 18 Years to 65 Years (Adult, Older Adult) Sex: All	• Cephalon • Teva Pharmaceutical Industries	• Industry	Study Start: October 2005 Primary Completion: Study Completion: July 2006 First Posted: September 29, 2005 Results First Posted: June 25, 2010 Last Update Posted: July 19, 2013	• Sleep Disorders Center of Alabama, Birmingham, Alabama, United States • Neurology Consultants of Tuscaloosa, P.C., Tuscaloosa, Alabama, United States • Pulmonary Associates, Phoenix, Arizona, United States • HOPE Research Institute, Phoenix, Arizona, United States • PsyPharm Clinical Research, Phoenix, Arizona, United States • PsyPharm Clinical Research Inc., Tucson, Arizona, United States • Neurology and Clinical Study Center, Little Rock, Arkansas, United States • Advanced Clinical Research Institute, Anaheim, California, United States • West Coast Clinical Trials, Inc, Long Beach, California, United States • Neuro-Therapeutics, Inc, Pasadena, California, United States • and 33 more
8	NCT00078377	Safety and Efficacy Study of Armodafinil (CEP-10953) in the Treatment of Excessive Sleepiness Associated With Narcolepsy Study Documents:	Title Acronym: Other Ids: C10953/3020/NA/MN	Completed	• Narcolepsy	• Drug: Armodafinil • Drug: Placebo	Study Type: Interventional Phase: Phase 3 Study Design: • Allocation: Randomized • Intervention Model: Parallel Assignment • Masking: Double • Primary Purpose: Treatment Outcome Measures: • Change From Baseline in Maintenance of Wakefullness Test (MWT) Score at 12 Weeks • Change From Baseline in Clinical Global Impression of Change (CGI-C) Score at 12 Weeks	Enrollment: 196 Age: 18 Years to 65 Years (Adult, Older Adult) Sex: All	• Cephalon • Teva Pharmaceutical Industries	• Industry	Study Start: March 2004 Primary Completion: January 2005 Study Completion: January 2005 First Posted: February 26, 2004 Results First Posted: January 21, 2010 Last Update Posted: July 19, 2013	

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
9	NCT00078312	Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/ Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder Study Documents:	Title Acronym: Other Ids: C10953/3023/ES/ MN	Completed	•Narcolepsy •Sleep Apnea, Obstructive •Sleep Apnea Syndromes •Shift-Work Sleep Disorder	•Drug: CEP-10953 (Armodafinil)	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Non-Randomized •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: Safety and Tolerability as Measured by Number of Participants With Adverse Events	Enrollment: 328 Age: 18 Years to 65 Years (Adult, Older Adult) Sex: All	•Cephalon •Teva Pharmaceutical Industries	•Industry	Study Start: January 2004 Primary Completion: July 2006 Study Completion: July 2006 First Posted: February 25, 2004 Results First Posted: February 22, 2010 Last Update Posted: July 19, 2013	•Pivotal Research Centers, Peoria, Arizona, United States •Central Phoenix Medical Clinic, LLC, Phoenix, Arizona, United States •Radiant Research - Tucson, Tucson, Arizona, United States •Central Arkansas Research, Hot Springs, Arkansas, United States •Arkansas Center for Sleep Medicine, Little Rock, Arkansas, United States •Bay Area Research Institute, Lafayette, California, United States •Pharmacology Research Institute, Los Alamitos, California, United States •Neuro-Therapeutics Inc., Pasadena, California, United States •Anderson Clinical Research, Redlands, California, United States •Synergy Clinical Research Center, San Diego, California, United States •and 40 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
10	NCT01638403	Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy. Study Documents:	Title Acronym: Other Ids: P09-15/ BF2.649 Harmony 1bis	Completed	•Treatment of Excessive Daytime Sleepiness in Narcolepsy	•Drug: BF2.649 •Drug: Vigil •Drug: palcebo	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Double (Participant, Investigator) •Primary Purpose: Treatment Outcome Measures: •Epworth Sleepiness Scale scores (ESS) •patient sleep diary •Maintenance of Wakefulness Test (MWT) •Test of Sustained Attention to Response Task (SART) •Clinical Global Impressions of Change •European Quality of life questionnaire (EQ-5D) •Patient's Global Opinion on the effect of treatment	Enrollment: 180 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Bioprojet	•Other	Study Start: November 2010 Primary Completion: April 2012 Study Completion: July 2012 First Posted: July 11, 2012 Results First Posted: No Results Posted Last Update Posted: January 31, 2017	•Evelyne DESCHAMPS DE PAILLETTE, Paris, France

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
11	NCT01067222	Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy Study Documents:	Title Acronym: Harmony1 Other Ids: •P07-03 / BF2.649 •2008-007866-46	Completed	•Narcolepsy •Excessive Daytime Sleepiness •Cataplexy •Sleep Disorders	•Drug: BF2.649 •Drug: Modafinil •Drug: Placebo	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Double (Participant, Investigator) •Primary Purpose: Treatment Outcome Measures: •Epworth Sleepiness Scale (ESS) •Sleep Diary: Number and duration of diurnal sleep and sleepiness episodes, number of cataplexy attacks •Maintenance of Wakefulness Test (MWT), Test of Sustained Attention to Response Task (SART).	Enrollment: 110 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Bioprojet	•Other	Study Start: May 2009 Primary Completion: July 2010 Study Completion: December 2010 First Posted: February 11, 2010 Results First Posted: No Results Posted Last Update Posted: June 11, 2012	•Neurocenter (EOC) of Southern Switzerland, Lugano, Switzerland
12	NCT01067235	Efficacy and Safety Study of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolespy Study Documents:	Title Acronym: Harmony2 Other Ids: •P07-07 / BF2.649 •2008-007845-29	Completed	•Narcolepsy •Cataplexy •Excessive Daytime Sleepiness	•Drug: BF2.649 •Drug: BF2.649 add on Modafinil	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Double (Participant, Investigator) •Primary Purpose: Treatment Outcome Measures: •Cataplexy attacks reported on sleep diary •Sleep Diary: number and duration of diurnal sleep and sleepiness episodes, •Maintenance of Wakefulness Test (MWT), Test of Sustained Attention to Response Task (SART). •Epworth Sleepiness Scale (ESS)	Enrollment: 14 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Bioprojet	•Other	Study Start: October 2009 Primary Completion: July 2010 Study Completion: July 2010 First Posted: February 11, 2010 Results First Posted: No Results Posted Last Update Posted: February 11, 2013	•Neurocenter (EOC) of Southern Switzerland, Lugano, Switzerland

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
13	NCT00174174	Provigil (Modafinil) Study by Taiwan Biotech Co. Study Documents:	Title Acronym: Other Ids: 920203I	Completed	•Narcolepsy •Cataplexy •Sleep Disorders •Hypersomnolence •Excessive Sleepiness	•Drug: Modafinil	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: Randomized •Intervention Model: Crossover Assignment •Masking: Double •Primary Purpose: Treatment Outcome Measures: •The change from baseline in the sleep latency. •Patient's assessment of general level of daytime sleepiness on ESS. •Patient's cognitive function assessed by psychomotor function test (Trail making test, and Digit Symbol Substitution Test). •Patient's sleep quality evaluated by PSQI. •Safety would be evaluated by tabulating and summarizing all adverse events reported.	Enrollment: 30 Age: 12 Years to 65 Years (Child, Adult, Older Adult) Sex: All	•National Taiwan University Hospital	•Other	Study Start: September 2003 Primary Completion: Study Completion: First Posted: September 15, 2005 Results First Posted: No Results Posted Last Update Posted: September 15, 2005	
14	NCT02051153	Neurochemical Modulation Cognitive Performance and Subjective Wellbeing In Healthy Controls Study Documents:	Title Acronym: ModCog Other Ids: A091967	Completed	•Cognitive Performance •Creativity •Motivation •Reward •Healthy Volunteers •Subjective Pleasure	•Drug: Modafinil •Drug: Placebo	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Triple (Participant, Investigator, Outcomes Assessor) •Primary Purpose: Basic Science Outcome Measures: •Neuropsychological measures •Physiological measures	Enrollment: 64 Age: 16 Years to 40 Years (Child, Adult) Sex: All	•Cambridge University Hospitals NHS Foundation Trust	•Other	Study Start: October 2009 Primary Completion: August 2011 Study Completion: September 2011 First Posted: January 31, 2014 Results First Posted: No Results Posted Last Update Posted: January 31, 2014	•Department of Psychiatry, Cambridge School of Clinical Medicine, Cambridge, Cambridgeshire, United Kingdom

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
15	NCT01684306	Pharmacological Cognitive Enhancement Study Documents:	Title Acronym: MODREST Other Ids: MODREST_2011	Completed	•Fluid Inteligence •Modafinil •Healthy Young Subjects •Resting State Networks	•Drug: Modafinil •Drug: Placebo	Study Type: Interventional Phase: Early Phase 1 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Double (Participant, Investigator) •Primary Purpose: Supportive Care Outcome Measures: Acute effects of modafinil on brain resting state networks in young healthy subjects	Enrollment: 26 Age: 25 Years to 35 Years (Adult) Sex: Male	•Università degli Studi 'G. d'Annunzio' Chieti e Pescara	•Other	Study Start: February 2011 Primary Completion: April 2011 Study Completion: January 2012 First Posted: September 12, 2012 Results First Posted: No Results Posted Last Update Posted: September 13, 2012	•Department of Neuroscience and Imaging, University "G. d'Annunzio", Chieti, Italy
16	NCT00424931	A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With Narcolepsy Study Documents:	Title Acronym: Other Ids: •CR013390 •C-2006-028	Completed	•Narcolepsy	•Drug: JNJ-17216498 •Drug: Modafinil	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Triple (Participant, Care Provider, Investigator) •Primary Purpose: Treatment Outcome Measures: •Explore the effectiveness of JNJ-17216498 in patients with narcolepsy as determined by the Maintenance of Wakefulness Test done throughout the study. •Explore the safety and tolerability of JNJ-17216498 in patients with narcolepsy by assessing adverse events, vital signs, laboratory results, vision tests, physical exam and ECGs.	Enrollment: 16 Age: 18 Years to 55 Years (Adult) Sex: All	•Alza Corporation, DE, USA	•Industry	Study Start: January 2007 Primary Completion: November 2007 Study Completion: December 2007 First Posted: January 22, 2007 Results First Posted: No Results Posted Last Update Posted: May 23, 2014	•Birmingham, Alabama, United States •Phoenix, Arizona, United States •Tucson, Arizona, United States •San Diego, California, United States •Stanford, California, United States •Spring Hill, Florida, United States •St Petersburg, Florida, United States •Macon, Georgia, United States •Danville, Indiana, United States •Fort Wayne, Indiana, United States •and 6 more